Mechanistically, CD68+ CAFs appear to enhance anti-tumor immune responses by promoting the secretion of CCL17 and CCL22, which facilitate regulatory T cell recruitment in a potentially regulatory feedback context (24). This evidence concerns the gene CCL22 and neoplasm.